Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY900009- Dose Escalation Phase · 1 trial · 1 indication
Clinically significant effects are study drug related serious adverse events (SAEs) and study drug related treatment emergent adverse events (TEAEs). A summary of all SAEs and all other non-SAEs regardless of causality is located in the Reported Adverse Events module.
| Arm | Type | Description |
|---|---|---|
| LY900009 | EXPERIMENTAL | Dose escalation phase: 2 milligrams (mg), 4 mg, 8 mg, 15 mg, 30 mg, 45 mg and 60mg LY900009 administered orally 3 times per week (Monday, Wednesday, Friday) for 4 weeks of a 28-day cycle. Dose confirmation phase: 30 mg LY900009 administered orally 3 times per week (Monday, Wednesday, Friday) for 4 weeks of a 28-day cycle. Participants experiencing clinical benefit may continue treatment unless discontinuation criteria are met. |
| Name | Type | Description |
|---|---|---|
| LY900009 - Dose Escalation Phase (Part A) | DRUG | 2 milligrams (mg), 4 mg, 8 mg, 15 mg, 30 mg, 45 mg and 60mg LY900009 administered orally 3 times per week (Monday, Wednesday, Friday) for 4 weeks of a 28-day cycle. Participants experiencing clinical benefit may continue treatment unless discontinuation criteria are met. |
| LY900009 - Dose Confirmation Phase (Part B) | DRUG | 30 mg LY900009 orally 3 times per week (Monday, Wednesday, Friday) for 4 weeks of a 28-day cycle. Participants experiencing clinical benefit may continue treatment unless discontinuation criteria are met. |
Inclusion Criteria: * The participants must be, in the judgment of the investigator, an appropriate candidate for experimental therapy after available standard therapies have ceased to provide clinical benefit for their disease. * The participants must have histological or cytological evidence of c...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
LY900009 is an investigational small molecule being studied for the treatment of advanced cancer. It is a Notch inhibitor that was evaluated in a Phase 1 clinical trial in patients with advanced cancer. The drug is not approved and remains in clinical development.
LY900009 targets the Notch signaling pathway, which is involved in cell differentiation and proliferation. By inhibiting Notch, the drug aims to interfere with cancer cell growth. This mechanism was the focus of its Phase 1 trial in advanced cancer.
LY900009 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol LLY. The company conducted a Phase 1 clinical trial of the drug in patients with advanced cancer.
LY900009 is in Phase 1 clinical development. A Phase 1 trial of the drug in advanced cancer has been completed. The drug is investigational and has not been approved by regulatory authorities.
LY900009 has been studied in one clinical trial, identified as NCT01158404, titled 'Notch Inhibitor in Advanced Cancer.' This Phase 1 trial enrolled 35 participants with advanced cancer in the United States and has been completed.
LY900009 is a Notch inhibitor, meaning it works by blocking the Notch signaling pathway. This mechanism was evaluated in a Phase 1 clinical trial for advanced cancer. The drug is being developed by Eli Lilly and Company.